JP2006504667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006504667A5 JP2006504667A5 JP2004527704A JP2004527704A JP2006504667A5 JP 2006504667 A5 JP2006504667 A5 JP 2006504667A5 JP 2004527704 A JP2004527704 A JP 2004527704A JP 2004527704 A JP2004527704 A JP 2004527704A JP 2006504667 A5 JP2006504667 A5 JP 2006504667A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- disease
- optionally
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 150000004982 aromatic amines Chemical class 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- -1 C 1-5 Alkoki Ci Chemical group 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 239000012948 isocyanate Substances 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 239000002243 precursor Substances 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 229910052739 hydrogen Chemical group 0.000 claims 3
- 239000001257 hydrogen Chemical group 0.000 claims 3
- 150000002513 isocyanates Chemical class 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010048873 Traumatic arthritis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000000010 aprotic solvent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 150000007529 inorganic bases Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40192102P | 2002-08-08 | 2002-08-08 | |
| PCT/US2003/024095 WO2004014870A1 (en) | 2002-08-08 | 2003-08-01 | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006504667A JP2006504667A (ja) | 2006-02-09 |
| JP2006504667A5 true JP2006504667A5 (https=) | 2006-09-21 |
Family
ID=31715757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004527704A Pending JP2006504667A (ja) | 2002-08-08 | 2003-08-01 | 炎症過程に関与するサイトカインの抑制剤としてのフッ素化フェニル−ナフタレニル−尿素化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6872726B2 (https=) |
| EP (1) | EP1549621A1 (https=) |
| JP (1) | JP2006504667A (https=) |
| AR (1) | AR040835A1 (https=) |
| AU (1) | AU2003257991A1 (https=) |
| CA (1) | CA2494824A1 (https=) |
| PE (1) | PE20040755A1 (https=) |
| TW (1) | TW200407113A (https=) |
| UY (1) | UY27924A1 (https=) |
| WO (1) | WO2004014870A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2494824A1 (en) * | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
| MXPA05012377A (es) | 2003-05-15 | 2006-05-25 | Arqule Inc | Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38. |
| EP1644341A1 (en) | 2003-06-30 | 2006-04-12 | Boehringer Ingelheim Pharmaceuticals Inc. | Process of making di-aryl urea compounds |
| CA2536293A1 (en) * | 2003-08-22 | 2005-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating copd and pulmonary hypertension |
| WO2006010082A1 (en) * | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
| JP2008517064A (ja) | 2004-10-19 | 2008-05-22 | アークル インコーポレイテッド | Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成 |
| CA2635888A1 (en) * | 2006-01-04 | 2007-07-19 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US20080045589A1 (en) * | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| EP2102173B1 (en) | 2006-12-22 | 2010-10-20 | F. Hoffmann-La Roche AG | Pyrimidyl derivatives as protein kinase inhibitors |
| CN101636397B (zh) * | 2007-04-13 | 2012-06-13 | 中国人民解放军军事医学科学院毒物药物研究所 | 脲类化合物、其制备方法及其医药用途 |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| AR076601A1 (es) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | Pirimidinas como agentes terapeuticos |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| DK2788349T3 (en) * | 2011-12-09 | 2017-01-30 | Chiesi Farm Spa | kinase inhibitors |
| KR102283876B1 (ko) | 2013-04-02 | 2021-07-29 | 옥슬러 액퀴지션즈 리미티드 | 키나제 저해제로서 유용한 우레아 유도체 |
| EP3083604A1 (en) * | 2013-12-20 | 2016-10-26 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| WO2016043079A1 (ja) * | 2014-09-19 | 2016-03-24 | 東レ・ファインケミカル株式会社 | ２'－トリフルオロメチル基置換芳香族ケトンの製造方法 |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| CA3015978A1 (en) | 2016-04-06 | 2017-10-12 | Topivert Pharma Limited | Kinase inhibitors |
| EP3500257B1 (en) | 2016-08-17 | 2025-07-02 | Icahn School of Medicine at Mount Sinai | Kinase inhibitor compounds, compositions, and methods of treating cancer |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| PY2311120A (es) * | 2022-03-01 | 2023-09-14 | Syngenta Crop Protection Ag | Compuestos herbicidas |
| CN116178248B (zh) * | 2023-02-28 | 2024-10-18 | 河南省锐达医药科技有限公司 | 一类萘基脲-哌啶类化合物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69230962T2 (de) | 1991-08-22 | 2000-10-05 | Raytheon Co., Lexington | Kristallzüchtungsverfahren zur Herstellung von grossflächigen GaAs und damit hergestellte Infrarot-Fenster/Kuppel |
| EP0647631B1 (de) * | 1993-10-12 | 2001-08-16 | BASF Aktiengesellschaft | Naphthylether, Verfahren zu ihrer Verwendung, sie enthaltende Mittel und ihre Verwendung als Fungizide |
| TR199902012T2 (xx) * | 1997-02-21 | 2000-01-21 | Bayer Aktiengesellschaft | Arils�lfonamidler ve analoglar� |
| WO1999023091A1 (en) | 1997-11-03 | 1999-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| DE69836563T2 (de) | 1997-12-22 | 2007-05-16 | Bayer Pharmaceuticals Corp., West Haven | INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN |
| JP3887769B2 (ja) | 1997-12-22 | 2007-02-28 | バイエル コーポレイション | 対称および非対称ジフェニル尿素を用いるｐ３８キナーゼの阻害 |
| JP3516012B2 (ja) | 1998-12-25 | 2004-04-05 | アークレイ株式会社 | 微量の蛋白質を測定するための組成物 |
| US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
| WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| NZ528846A (en) | 1999-03-12 | 2005-05-27 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents |
| WO2000055152A1 (en) | 1999-03-12 | 2000-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| WO2001036403A1 (en) * | 1999-11-16 | 2001-05-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Urea derivatives as anti-inflammatory agents |
| MXPA03009000A (es) | 2001-04-13 | 2004-02-12 | Boehringer Ingelheim Pharma | Compuestos benzo-fusionados 1,4-disustituidos. |
| WO2002092576A1 (en) * | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
| CA2494824A1 (en) * | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
-
2003
- 2003-08-01 CA CA002494824A patent/CA2494824A1/en not_active Abandoned
- 2003-08-01 US US10/632,998 patent/US6872726B2/en not_active Expired - Lifetime
- 2003-08-01 WO PCT/US2003/024095 patent/WO2004014870A1/en not_active Ceased
- 2003-08-01 EP EP03784873A patent/EP1549621A1/en not_active Withdrawn
- 2003-08-01 AU AU2003257991A patent/AU2003257991A1/en not_active Abandoned
- 2003-08-01 JP JP2004527704A patent/JP2006504667A/ja active Pending
- 2003-08-04 UY UY27924A patent/UY27924A1/es not_active Application Discontinuation
- 2003-08-04 PE PE2003000769A patent/PE20040755A1/es not_active Application Discontinuation
- 2003-08-07 TW TW092121657A patent/TW200407113A/zh unknown
- 2003-08-08 AR AR20030102875A patent/AR040835A1/es unknown
-
2004
- 2004-09-14 US US10/940,898 patent/US7279475B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006504667A5 (https=) | ||
| JP7012668B2 (ja) | ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物 | |
| JP6854386B2 (ja) | リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物 | |
| JP2018517731A5 (https=) | ||
| CN105541891B (zh) | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 | |
| JP2004506611A5 (https=) | ||
| TW200417546A (en) | New compounds | |
| JP2008515852A5 (https=) | ||
| WO2001025190A1 (en) | Novel diarylamide derivatives and use thereof as medicines | |
| JP2009256327A (ja) | シクロアルカンジカルボン酸モノエステルの製造方法 | |
| KR20050122264A (ko) | P38 키나아제 저해제로서 유용한 퀴나졸린 화합물 | |
| TW200521122A (en) | Method of preparing 1,2,4-triazole compounds and intermediates thereof | |
| JP2009544756A5 (https=) | ||
| JP2008544965A (ja) | ｐ３８キナーゼ阻害剤としての二環式誘導体 | |
| JP2020517676A5 (https=) | ||
| RU2349588C2 (ru) | Способы получения производных изотиазола | |
| KR101728443B1 (ko) | 2-아미노니코틴산벤질에스테르 유도체의 제조 방법 | |
| CA2498754A1 (en) | Benzimidazolones and their use as cytokine inhibitors | |
| JP2016069321A (ja) | 環構造を有するジカルボン酸モノエステルの製造方法、ジカルボン酸モノエステルアミン塩、ジカルボン酸モノエステルを用いた液晶化合物の製造方法 | |
| CN111836811B (zh) | 制备可溶性鸟苷酸环化酶刺激剂的方法 | |
| JPWO2017014201A1 (ja) | 含窒素複素環化合物 | |
| KR20160027537A (ko) | 실로도신의 제조방법 | |
| JPS6072853A (ja) | 新規２−アミノ−アルケニルスルホニル尿素 | |
| JPH03279361A (ja) | ピペラジニルキノロン誘導体の製造方法 | |
| WO2013064468A1 (en) | Indole inhibitors of crac |